Lenalidomide Global Market Report 2026

Lenalidomide is an immunomodulatory medication belonging to the class of thalidomide analogs. It is mainly used for the treatment of multiple myeloma, a cancer of plasma cells, and for managing certain forms of myelodysplastic syndromes (MDS). Lenalidomide works by modifying immune system activity and suppressing the growth and survival of cancer cells.

The primary types of lenalidomide include 5 mg capsules, 10 mg capsules, 15 mg capsules, and 25 mg capsules. The 5 mg capsules contain 5 milligrams of the active drug ingredient. Lenalidomide is used for applications such as multiple myeloma (MM), myelodysplastic syndromes (MDS), lymphoma, and others, and is utilized in hospitals, cancer treatment centers, and research institutes.

Tariffs have impacted the lenalidomide market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation inputs used in capsule manufacturing. These effects have been most evident in branded lenalidomide products across North America and Europe, where global API sourcing is common. Asia-Pacific manufacturers have experienced pricing pressure due to trade-related dependencies. However, tariffs have supported domestic API production and accelerated the expansion of generic lenalidomide manufacturing, improving long-term supply resilience.

The lenalidomide market research report is one of a series of new reports from The Business Research Company that provides lenalidomide market statistics, including lenalidomide industry global market size, regional shares, competitors with a lenalidomide market share, detailed lenalidomide market segments, market trends and opportunities, and any further data you may need to thrive in the lenalidomide industry. This lenalidomide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lenalidomide market size has grown strongly in recent years. It will grow from $12.79 billion in 2025 to $13.77 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to established clinical efficacy of lenalidomide in multiple myeloma, approval for treatment of myelodysplastic syndromes, improved survival outcomes compared to older therapies, widespread adoption in oncology treatment guidelines, availability of multiple dosage strengths for flexible therapy.

The lenalidomide market size is expected to see strong growth in the next few years. It will grow to $17.83 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to rising global prevalence of multiple myeloma, increasing adoption of maintenance therapy protocols, expanding access to oncology treatments in emerging markets, growing use of combination and sequential therapy strategies, continued demand for effective immunomodulatory cancer drugs. Major trends in the forecast period include continued use of lenalidomide as a backbone therapy in multiple myeloma, growing adoption of lenalidomide in combination treatment regimens, increasing availability of generic lenalidomide products, rising use of maintenance therapy in long-term myeloma management, expansion of lenalidomide use in additional hematological indications.

The rising prevalence of blood cancer cases is expected to drive the growth of the lenalidomide market in the coming years. Blood cancer includes a group of malignancies that affect blood cells, bone marrow, or the lymphatic system, disrupting normal blood formation and immune function. The occurrence of blood cancer is increasing due to factors such as aging populations, exposure to environmental toxins, genetic predisposition, and lifestyle-related influences. The lenalidomide market supports blood cancer treatment by providing therapies that modulate immune responses, suppress cancer cell growth, and promote the elimination of malignant cells. For example, in January 2023, according to the Cancer Facts and Figures 2023 report published by the American Cancer Society, a US-based non-profit organization, the estimated number of new myeloma cases in the United States reached 35,730 in 2023, including 19,860 males and 15,870 females. In addition, around 184,720 individuals were expected to be diagnosed with leukemia, lymphoma, or myeloma in 2023. Therefore, the increasing prevalence of blood cancer is fueling the growth of the lenalidomide market.

Major companies operating in the lenalidomide market are concentrating on developing innovative solutions, such as complex generic capsule formulations, to improve drug accessibility and patient adherence. Complex generic capsule formulations are advanced versions of existing medicines designed to match the original product's safety and effectiveness while addressing manufacturing or delivery challenges. For instance, in March 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, partnered with Natco Pharma Limited, an India-based pharmaceutical company, to launch additional dosage strengths of 2.5 mg and 20 mg for the generic version of Revlimid lenalidomide capsules in the United States. This expansion improved patient access to an essential therapy for multiple myeloma and related conditions and supported a wider range of treatment options by making a broader spectrum of lenalidomide capsule strengths available by prescription.

In December 2023, Lotus Pharmaceutical, a US-based biopharmaceutical company, partnered with Fuji Pharma Co. Ltd. to use Fuji Pharma's expertise and market presence for distributing Lotus's lenalidomide capsules, a generic version of Revlimid, in the Japanese market. This partnership strengthens Lotus's commercial presence in Japan by enabling local market access and regulatory-compliant distribution, while also enhancing Fuji Pharma's oncology portfolio through the addition of a high-value hematology therapy. Fuji Pharma Co. Ltd. is a Japan-based manufacturer and distributor of medical products.

Major companies operating in the lenalidomide market are Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd, Aurobindo Pharma, Dr. Reddy's Laboratories, Cipla Limited, Apotex Inc, Zydus Lifesciences Limited, Alvogen, Lotus Pharmaceutical, Natco Pharma Limited, Accord Healthcare, Avra Laboratories Pvt. Ltd., Camber Pharmaceuticals Inc., Rochem International Inc, Florencia Healthcare, Alleviare Life Sciences Pvt Ltd., Sarv Biolabs Pvt Ltd, Speciality Medicines Private Limited, Healthiza Lifescience Private Limited.

North America was the largest region in the lenalidomide market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lenalidomide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lenalidomide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lenalidomide market consists of sales of buccal patches, oral tablets, capsules, and powders. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lenalidomide Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses lenalidomide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lenalidomide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lenalidomide market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: 5Mg Capsules; 10Mg Capsules; 15Mg Capsules; 25Mg Capsules
• 2) By Application: Multiple Myeloma (MM); Myelodysplastic Syndromes (MDS); Lymphoma; Other Applications
• 3) By End-User: Hospitals; Cancer Treatment Centers; Research Institutes
• Companies Mentioned: Bristol-Myers Squibb Company; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Ltd; Aurobindo Pharma; Dr. Reddy's Laboratories; Cipla Limited; Apotex Inc; Zydus Lifesciences Limited; Alvogen; Lotus Pharmaceutical; Natco Pharma Limited; Accord Healthcare; Avra Laboratories Pvt. Ltd.; Camber Pharmaceuticals Inc.; Rochem International Inc; Florencia Healthcare; Alleviare Life Sciences Pvt Ltd.; Sarv Biolabs Pvt Ltd; Speciality Medicines Private Limited; Healthiza Lifescience Private Limited.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.